Research and development progress of the novel acid suppression drugs potassium-competitive acid blockers

doi:10.12092/j.issn.1009-2501.2018.03.019

Abstract

Abstract:

The advent of proton pump inhibitors represents an important milestone in the treatment of acid related diseases. However, these drugs have some deficiencies in pharmacokinetics and pharmacodynamics. Potassium-competitive acid blockers reversibly bind to proton pumps in a competitive manner with potassium ions, thereby inhibiting gastric acid secretion and having multiple advantages. In order to provide a new reference for the treatment of acid related diseases, the research and development experience and pharmacological characteristics and clinical research of these drugs are reviewed, and the focuses are on the already listed revaprazan and vonoprazan.

Key words: potassium-competitive acid blockers, proton pump inhibitors, acid-related diseases, revaprazan, vonoprazan

CLC Number:

R975

ZHAO Shifeng, WANG Ronghua. Research and development progress of the novel acid suppression drugs potassium-competitive acid blockers[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 352-360.

References

［1］Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases［J］. Pharmacol Ther, 2016, 168: 12-22.
［2］Yang ZC, Yu F, Wang YQ, et al. Stereoselective pharmacodynamics and pharmacokinetics of proton pump inhibitors［J］. Curr Drug Metab, 2016, 17(7): 692-702.
［3］Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases［J］. Pharmacol Ther, 2005, 108(3): 294-307.
［4］刘敏, 肖飞燕, 王晓飞, 等. 基因多态性、药物联用和临床因素对氯吡格雷疗效的影响及相关的基因型分布［J］. 中国临床药理学与治疗学, 2015, 20(8): 915-922.
［5］Geibel JP. Role of potassium in acid secretion［J］. World J Gastroenterol, 2005, 11(34): 5259-5265.
［6］Scott DR, Marcus EA, Sachs G. Vonoprazan: marked competition for PPIs［J］? Dig Dis Sci, 2016, 61(7): 1783-1784.
［7］Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning［J］? Curr Opin Pharmacol, 2008, 8(6): 677-684.
［8］Han KS, Kim YG, Lee JW, et al. Blood partition and protein binding of a new reversible proton pump inhibitor, YH1885［J］. Biopharm Drug Dispos, 1998, 19(6): 413-415.
［9］Yu KS, Bae KS, Shon JH, et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers［J］. J Clin Pharmacol, 2004, 44(1): 73-82.
［10］Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects［J］. J Gastroen Hepatol, 2010, 25(10): 1618-1625.
［11］Chung IS, Choi MG, Park SH. Revaprazan, a novel acid pump antagonist, for duodenal ulcer: Results of a double-blind, randomized, parallel, multicenter phase III clinical trial［J］. Korean J Gastrointest Endosc, 2005, 31: 17-24.
［12］Chang R, Chung IS, Park SH. Phase III clinical trial of revaprazan (Revanex(R)) for gastric ulcer［J］. Korean J Gastrointest Endosc, 2007, 34: 312-319.
［13］Kim YG, Jang BI, Kim TN. A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection［J］. Gut Liver, 2010, 4(1): 25-30.
［14］Ock CY, Lim YJ, Kim YJ, et al. Acid pump antagonist-provoked HSP27 dephosphorylation and accentuation rescues stomach from indomethacin-induced damages［J］. J Dig Dis, 2011, 12(2): 71-81.
［15］Kim JH, Kim EH, Ock C, et al. Mitigating endoplasmic reticulum stress with revaprazan ameliorates stress‐related mucosal disease［J］. J Gastroen Hepatol, 2012, 27(1): 120-129.
［16］Lee JS, Cho JY, Song H, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling［J］. J Clin Biochem Nutr, 2012, 51(2): 77-83.
［17］Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438)［J］. Adv Ther, 2016, 33(7): 1140-1157.
［18］Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male japanese/non-japanese subjects［J］. Clin Transl Gastroen, 2015, 6(6): e94.
［19］Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects［J］. Aliment Pharmacol Ther, 2015, 41(7): 636-648.
［20］Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations［J］. Clin Pharmacokinet, 2016, 55(4): 409-418.
［21］Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker ［J］. Xenobiotica, 2016, 7(14): 1-8.
［22］Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype ［J］. Aliment Pharmacol Ther, 2016, 43(10): 1048-1059.
［23］Jenkins H, Jenkins R, Patat A. Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study［J］. Clin Drug Investig, 2017, 37(3): 311-316.
［24］Sakurai Y, Shiino M, Horii S, et al. Pharmacokinetic drug-drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy Japanese men［J］. Clin Drug Investig, 2017, 37(1): 39-49.
［25］Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker (P-CAB) with lansoprazole in animals［J］. J Pharmacol Exp Ther, 2011, 337(3): 797-804.
［26］Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study［J］. Aliment Pharmacol Ther, 2015, 42(6): 719-730.
［27］ Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs.lansoprazole in patients with gastric or duodenal ulcers-results from two phase 3, non-inferiority randomised controlled trials［J］. Aliment Pharmacol Ther, 2017, 45(2): 240-252.
［28］Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study［J］. Curr Ther Res Clin E, 2016, 81/82: 1-7.
［29］Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis［J］. Aliment Pharmacol Ther, 2016, 43(2): 240-251.
［30］Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesopHagitis［J］. Aliment Pharmacol Ther, 2015, 42(6): 685-695.
［31］Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study［J］. Gut, 2016, 65(9): 1439-1446.
［32］Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy［J］. Am J Gastroenterol, 2016, 111(7): 949-956.
［33］Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against helicobacter pylori［J］. J Gastrointestin Liver Dis, 2016, 25(3): 283-288.
［34］Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice［J］. J Dig Dis, 2016, 17(10): 670-675.
［35］Kawai T, Ashida K, Mizokami Y, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial ［J］. Gastroenterology, 2014, 146(5): S739.
［36］Mizokami Y, Ashida K, Soen S, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial［J］. Gastroenterology, 2014, 146(5): S739.
［37］Maruoka D, Arai M, Kasamatsu S, et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score‐matching analysis［J］. Dig Endosc, 2017, 29(1): 57-64.
［38］Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial［J］. Dig Endosc, 2017, 29(5): 576-583.
［39］Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis［J］. Digestion, 2017, 95(2): 156-161.
［40］Asaoka, Nagahara, Hojo, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia［J］. Biomed Rep, 2017, 6(2): 175-180.
［41］Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy［J］. World J Gastroenterol, 2017, 23(4): 668-675.
［42］Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of helicobacter pylori［J］. Digestion, 2016, 94(4): 240-246.
［43］Astruc B, Jenkins H, Jenkins R. Effect of therapeutic and supratherapeutic doses of vonoprazan on the QT/QTc interval in a phase I randomized study in healthy subjects.［J］. Clin Transl Sci, 2017, 10(3): 208-216.
［44］Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan- amoxicillin- clarithromycin triple therapy for first-line Helicobacter pylori eradication［J］. Scand J Gastroenterol, 2017, 52(2): 238-241.
［45］Song W, Zhang X, Li S, et al. Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists.［J］. Chem Biol Drug Des, 2015, 85(3): 306-314.
［46］Yoon YA, Chan SP, Cha MH, et al. Novel pyrimidines as acid pump antagonists (APAs)［J］. Bioorg Med Chem Lett, 2010, 20(19): 5735-5738.
［47］Li W, Yang Y, Tian Y, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension［J］. Int J Pharm, 2011, 408(1/2): 157-162.
［48］Arikawa Y, Hasuoka A, Nishida H, et al. Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs) ［J］. Bioorg Med Chem Lett, 2015, 25(10): 2037-2040.
［49］Huang NY, Wang WB, Chen L, et al. Design, synthesis and biological evaluation of bisabolangelone oxime derivatives as potassium-competitive acid blockers (P-CABs) ［J］. Bioorg Med Chem Lett, 2016, 26(9): 2268-2272.

[1]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[2]	HUANG Qiong, DU Jie, CHENG Shuqiao, GONG Zhicheng. Progress of proton pump inhibitors using in cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1179-1187.